<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649712</url>
  </required_header>
  <id_info>
    <org_study_id>xzxy20160106</org_study_id>
    <nct_id>NCT02649712</nct_id>
  </id_info>
  <brief_title>Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction</brief_title>
  <official_title>Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuzhou Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the clinical effectiveness and long-term outcomes
      between patients with malignant hilar biliary obstruction who are treated by unilateral or
      bilateral stenting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malignant hilar biliary obstruction is a common clinical manifestation and it can be caused
      by cholangiocarcinoma, gallbladder carcinoma, liver cancer, or other metastatic carcinoma.
      Most patients with malignant hilar biliary obstruction are unresectable at diagnosis. Biliary
      stenting has been widely used in palliative treatment of malignant hilar biliary obstruction.

      Hilar biliary obstruction usually involves the bifurcation of the biliary tract. Some
      researchers recommended unilateral stenting for malignant hilar biliary obstruction because
      drainage of 25% of entire liver can achieve the clinical success of biliary drainage.
      However, some researchers recommended bilateral stenting for malignant hilar biliary
      obstruction because some researches demonstrated that bilateral stenting can achieve a longer
      stent patency.In addition, there was no significant difference in post stenting survival
      between patients who were treated by unilateral or bilateral stenting. Therefore, it remains
      under debate whether unilateral or bilateral stenting is better in the treatment of malignant
      hilar biliary obstruction.

      The purpose of this study is to compare the clinical effectiveness and long-term outcomes
      between patients with malignant hilar biliary obstruction who are treated by unilateral or
      bilateral stenting.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stent patency (Stent dysfunction is suspected when the patient experiences recurrence of jaundice)</measure>
    <time_frame>From the date of randomization until the date of first documented stent dysfunction, assessed up to 10 months</time_frame>
    <description>Stent dysfunction is suspected when the patient experiences recurrence of jaundice.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of randomization until the date of first documented death from any cause, assessed up to 12 months</time_frame>
    <description>From the date of randomization until the date of first documented death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent dysfunction free-patient survival</measure>
    <time_frame>From the date of randomization until the date of first documented stent dysfunction or the date of death from any cause, whichever came first, assessed up to 10 months.</time_frame>
    <description>From the date of randomization until the date of first documented stent dysfunction or the date of death from any cause, whichever came first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <condition>Gallbladder Carcinoma</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Unilateral stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo placement of unilateral biliary stent on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bilateral stents</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo placement of bilateral biliary stents on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>biliary stent</intervention_name>
    <description>Self-expandable biliary nitinol alloys stent</description>
    <arm_group_label>Unilateral stent</arm_group_label>
    <arm_group_label>Bilateral stents</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Malignant hilar biliary obstruction;

          2. Unresectable cases

        Exclusion Criteria:

          1. Bismuth I patients;

          2. inability to obtain informed consent;

          3. Eastern Cooperative Oncology Group performance status of 4;

          4. severe dysfunction in other organs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chi Cao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuzhou Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xuzhou Central Hospital</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Iwano H, Ryozawa S, Ishigaki N, Taba K, Senyo M, Yoshida K, Sakaida I. Unilateral versus bilateral drainage using self-expandable metallic stent for unresectable hilar biliary obstruction. Dig Endosc. 2011 Jan;23(1):43-8. doi: 10.1111/j.1443-1661.2010.01036.x. Epub 2010 Nov 30.</citation>
    <PMID>21198916</PMID>
  </reference>
  <reference>
    <citation>Yasuda I, Mukai T, Moriwaki H. Unilateral versus bilateral endoscopic biliary stenting for malignant hilar biliary strictures. Dig Endosc. 2013 May;25 Suppl 2:81-5. doi: 10.1111/den.12060. Review.</citation>
    <PMID>23617655</PMID>
  </reference>
  <reference>
    <citation>Liberato MJ, Canena JM. Endoscopic stenting for hilar cholangiocarcinoma: efficacy of unilateral and bilateral placement of plastic and metal stents in a retrospective review of 480 patients. BMC Gastroenterol. 2012 Aug 9;12:103. doi: 10.1186/1471-230X-12-103.</citation>
    <PMID>22873816</PMID>
  </reference>
  <reference>
    <citation>Gwon DI, Ko GY, Sung KB, Yoon HK, Shin JH, Hyoung Kim J, Kim J, Oh JY. Percutaneous biliary metallic stent placement in patients with unilobar portal vein occlusion caused by advanced hilar malignancy: outcome of unilateral versus bilateral stenting. AJR Am J Roentgenol. 2011 Oct;197(4):795-801. doi: 10.2214/AJR.11.6424.</citation>
    <PMID>21940566</PMID>
  </reference>
  <reference>
    <citation>Mukai T, Yasuda I, Nakashima M, Doi S, Iwashita T, Iwata K, Kato T, Tomita E, Moriwaki H. Metallic stents are more efficacious than plastic stents in unresectable malignant hilar biliary strictures: a randomized controlled trial. J Hepatobiliary Pancreat Sci. 2013 Feb;20(2):214-22. doi: 10.1007/s00534-012-0508-8.</citation>
    <PMID>22415652</PMID>
  </reference>
  <reference>
    <citation>Bulajic M, Panic N, Radunovic M, Scepanovic R, Perunovic R, Stevanovic P, Ille T, Zilli M, Bulajic M. Clinical outcome in patients with hilar malignant strictures type II Bismuth-Corlette treated by minimally invasive unilateral versus bilateral endoscopic biliary drainage. Hepatobiliary Pancreat Dis Int. 2012 Apr;11(2):209-14.</citation>
    <PMID>22484591</PMID>
  </reference>
  <reference>
    <citation>Inal M, Akgül E, Aksungur E, Seydaoğlu G. Percutaneous placement of biliary metallic stents in patients with malignant hilar obstruction: unilobar versus bilobar drainage. J Vasc Interv Radiol. 2003 Nov;14(11):1409-16.</citation>
    <PMID>14605106</PMID>
  </reference>
  <reference>
    <citation>Naitoh I, Ohara H, Nakazawa T, Ando T, Hayashi K, Okumura F, Okayama Y, Sano H, Kitajima Y, Hirai M, Ban T, Miyabe K, Ueno K, Yamashita H, Joh T. Unilateral versus bilateral endoscopic metal stenting for malignant hilar biliary obstruction. J Gastroenterol Hepatol. 2009 Apr;24(4):552-7. doi: 10.1111/j.1440-1746.2008.05750.x. Epub 2009 Feb 12.</citation>
    <PMID>19220678</PMID>
  </reference>
  <reference>
    <citation>Li M, Wu W, Yin Z, Han G. [Unilateral versus bilateral biliary drainage for malignant hilar obstruction: a systematic review and meta-analysis]. Zhonghua Gan Zang Bing Za Zhi. 2015 Feb;23(2):118-23. doi: 10.3760/cma.j.issn.1007-3418.2015.02.009. Review. Chinese.</citation>
    <PMID>25880978</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We wil share all data of this study. We aim to show our data by publishing article. The data may be available on March 2019.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

